Citigroup Inc Heron Therapeutics, Inc. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 2,476,529 shares of HRTX stock, worth $2.72 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,476,529
Previous 51,953
4666.86%
Holding current value
$2.72 Million
Previous $107,000
2861.68%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding HRTX
# of Institutions
185Shares Held
134MCall Options Held
61.1KPut Options Held
2.06M-
Rubric Capital Management LP New York, NY29.1MShares$32 Million0.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.2MShares$11.3 Million0.02% of portfolio
-
Clearline Capital LP New York, NY9.71MShares$10.7 Million0.62% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA8.75MShares$9.63 Million21.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.46MShares$9.31 Million0.0% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $131M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...